One connector, four scholarly indexes, real DOIs and legal free PDFs. Works in Claude and ChatGPT.
Paste it into Claude or ChatGPT as a custom connector. 3-day free trial.
Kate M. Bubar, Kyle Reinholt, Stephen M. Kissler, Marc Lipsitch, Sarah E. Cobey, Yonatan H. Grad, Daniel B. Larremore
When a vaccine for COVID-19 becomes available, limited initial supply will raise the question of how to prioritize the available doses and thus underscores the need for transparent, evidence-based strategies that relate knowledge of, and uncertainty in, disease transmission, risk, vaccine efficacy, and existing population immunity. Here, we employ a model-informed approach to vaccine prioritization that evaluates the impact of prioritization strategies on cumulative incidence and mortality and accounts for population factors such as age, contact structure, and seroprevalence, and vaccine factors including imperfect and age-varying efficacy. This framework can be used to evaluate and compare existing strategies, and it can also be used to derive an optimal prioritization strategy to minimize mortality or incidence. We find that a transmission-blocking vaccine should be prioritized to adults ages 20-49y to minimize cumulative incidence and to adults over 60y to minimize mortality. Direct vaccination of adults over 60y minimizes mortality for vaccines that do not block transmission. We also estimate the potential benefit of using individual-level serological tests to redirect doses to only seronegative individuals, improving the marginal impact of each dose. We argue that this serology-informed vaccination approach may improve the efficiency of vaccination efforts while partially addressing existing inequities in COVID-19 burden and impact.
Formatted from the source metadata, not typed by hand. For a whole reference list, use the citation generator or ask your assistant through Find Research.
Bubar, K. M., Reinholt, K., Kissler, S. M., Lipsitch, M., Cobey, S. E., Grad, Y. H., & Larremore, D. B. (2021). Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science, 371(6532), 916–921. https://doi.org/10.1126/science.abe6959
Bubar, Kate M., et al. "Model-informed COVID-19 vaccine prioritization strategies by age and serostatus." Science, vol. 371, no. 6532, 2021, pp. 916–921, https://doi.org/10.1126/science.abe6959.
Bubar, Kate M., Kyle Reinholt, Stephen M. Kissler, Marc Lipsitch, Sarah E. Cobey, Yonatan H. Grad, and Daniel B. Larremore. "Model-informed COVID-19 vaccine prioritization strategies by age and serostatus." Science 371, no. 6532 (2021): 916–921. https://doi.org/10.1126/science.abe6959.
Bubar K. M., Reinholt K., Kissler S. M. [и др.] Model-informed COVID-19 vaccine prioritization strategies by age and serostatus // Science. — 2021. — Vol. 371, № 6532. — P. 916–921. — URL: https://doi.org/10.1126/science.abe6959
@article{bubar2021modelinformed,
title = {{Model-informed COVID-19 vaccine prioritization strategies by age and serostatus}},
author = {Kate M. Bubar and Kyle Reinholt and Stephen M. Kissler and Marc Lipsitch and Sarah E. Cobey and Yonatan H. Grad and Daniel B. Larremore},
journal = {Science},
year = {2021},
volume = {371},
number = {6532},
pages = {916--921},
doi = {10.1126/science.abe6959},
url = {https://doi.org/10.1126/science.abe6959}
}TY - JOUR AU - Bubar, Kate M. AU - Reinholt, Kyle AU - Kissler, Stephen M. AU - Lipsitch, Marc AU - Cobey, Sarah E. AU - Grad, Yonatan H. AU - Larremore, Daniel B. TI - Model-informed COVID-19 vaccine prioritization strategies by age and serostatus JO - Science VL - 371 IS - 6532 SP - 916 EP - 921 PY - 2021 DA - 2021/01/21 DO - 10.1126/science.abe6959 UR - https://doi.org/10.1126/science.abe6959 ER -
Add Find Research to Claude or ChatGPT and ask in plain language. The assistant reads this record, finds the papers around it and cites only what it actually found:
Setup takes about a minute: add the connector, then start the free trial.
Record from OpenAlex; open-access location from Unpaywall and the indexes. Find Research links only to legal copies.